1-8 of 8
David F. Claxton, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.

Janice Gabrilove, MD, Stefan Faderl, MD, Harry P Erba, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Stephen Eckert, Ph.D, Dirk Huebner, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 2061.
https://doi.org/10.1182/blood.V114.22.2061.2061
Published: 2009
Journal Articles

Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are ≥ 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.

Harry P Erba, Stefan Faderl, MD, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Stephen Eckert, Ph.D, Dirk Huebner, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 2083.
https://doi.org/10.1182/blood.V114.22.2083.2083
Published: 2009
Journal Articles

Long Term Survival After Sirolimus Based Non-Ablative Alternative Donor Transplantation.

Jon Karch, BSc, Eric Schaefer, M.A., W. Chritopher Ehmann, MD, Michelle Carraher, BA, Giampaolo Talamo, MD, Witold B Rybka, MD, David F. Claxton, M.D.
Journal: Blood
Blood (2009) 114 (22): 1212.
https://doi.org/10.1182/blood.V114.22.1212.1212
Published: 2009
Journal Articles

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.

Guillermo Garcia-Manero, MD, Selina Luger, MD, Parameswaran Venugopal, MD, Lori J. Maness, MD, Meir Wetzler, MD, Jessica Altman, MD, David F. Claxton, M.D., Stephen Strickland, MD, Stefan Faderl, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 1758.
https://doi.org/10.1182/blood.V114.22.1758.1758
Published: 2009
Journal Articles

Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.

Stefan Faderl, MD, Harry P Erba, David F. Claxton, M.D., M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Elizabeth Anderson, Elly Barry, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 4155.
https://doi.org/10.1182/blood.V114.22.4155.4155
Published: 2009
Journal Articles

Sirolimus for Graft-Versus-Host-Diseases Prophylaxis in Non-Myeloablative Matched Related Transplantation: Safety and Efficacy.

Hong Zheng, MD, PhD, Michelle Carraher, BA, Eric Schaefer, M.A., Giampaolo Talamo, MD, W. Christopher Ehmann, MD, Witold Rybka, David F. Claxton, M.D.
Journal: Blood
Blood (2009) 114 (22): 4329.
https://doi.org/10.1182/blood.V114.22.4329.4329
Published: 2009
Journal Articles

Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML).

David F. Claxton, M.D., Thomas J Myers, MD, FACP, Harry P Erba, Stefan Faderl, MD, M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Clay R Warnock, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 4162.
https://doi.org/10.1182/blood.V114.22.4162.4162
Published: 2009
Journal Articles

Successful Treatment of Advanced and Refractory AML with Sirolimus Based Non-Myeloablative Allogeneic Stem Cell Transplantation.

David F. Claxton, M.D., Christopher Ehmann, M.D., Witold Rybka, M.D.
Journal: Blood
Blood (2004) 104 (11): 2760.
https://doi.org/10.1182/blood.V104.11.2760.2760
Published: 2004